Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNA), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.
Medicenna Therapeutics (MDNA) is a clinical-stage immunotherapy company at the forefront of developing novel and highly selective versions of IL-2, IL-4, and IL-13 superkines and first-in-class Empowered Cytokines (ECs). With a mission to lead in the development and commercialization of targeted ECs and superkines, Medicenna aims to revolutionize treatment for a broad range of cancers and immune-mediated diseases. The company leverages its expertise and collaborates with world-class researchers to create unique superkines.
Medicenna's innovative approach allows these superkines to function either as standalone short or long-acting therapeutics or to be fused with pro-apoptotic proteins. This fusion precisely delivers potent cell-killing agents to cancer cells, the immunosuppressive tumor micro-environment, and cancer stem cells, sparing healthy cells from harm. Additionally, these superkines can be fused with antibodies to create novel 'immunocytokines' or combined with other treatment modalities.
Currently, Medicenna is engaged in various promising projects. A notable recent achievement includes the characterization of its tumor-targeting and activatable T-MASK platform, designed to enhance tumor accumulation and tolerability of potent immune modulators. This innovation was presented at a significant conference on November 3, 2023.
As Medicenna continues to advance its pipeline of targeted treatments, it remains committed to transforming the therapeutic landscape for cancer and immune-related conditions. The company's financial health is supported by strategic partnerships and a focus on groundbreaking research and development.
Medicenna Therapeutics announced that Dr. Fahar Merchant, its President and CEO, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 10:00 AM ET. The presentation will provide an overview of the company's immuno-oncology developments, including its promising MDNA11 and MDNA55 assets, focused on cancer treatment. A live webcast will be accessible here. A replay will be available post-event on Medicenna's website.
Medicenna Therapeutics Corp. (NASDAQ: MDNA; TSX: MDNA) announced promising preclinical data for MDNA19-MDNA413, a dual-specific cytokine developed from their BiSKITs™ platform, presented at the AACR Annual Meeting. This innovative therapy selectively activates anti-cancer immune cells while inhibiting pro-tumoral macrophage polarization. Key findings highlighted a 209-fold and 90-fold enhancement in CD8/Treg and NK/Treg ratios, respectively, and effective suppression of IL-13 induced M2a macrophage polarization. Medicenna plans to advance its development and regulatory submissions for MDNA11, another promising superkine therapy.
Medicenna Therapeutics Corp. (NASDAQ: MDNA), a clinical stage immuno-oncology company, announced preclinical data showcasing the effectiveness of MDNA11 and its BiSKITsTM program. In a murine solid tumor model, MDNA11, both alone and in combination with anti-PD-1 therapy, achieved tumor growth inhibition and complete responses. The findings indicate that BiSKITsTM can effectively address immunosuppressive tumor environments. Medicenna aims to present further results on its dual-specific cytokine, enhancing the potential of its Superkine platform in targeting “cold” tumors.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced the upcoming presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting 2021. Scheduled for April 10-15, 2021, the poster will focus on preclinical studies of a bispecific Superkine targeting IL-2 and IL-4/IL-13 pathways. The abstract is titled Modulation of Immune Responses to Cancer by Bi-specific IL-2/IL-13 Superkines and will be available for on-demand viewing post-presentation. Medicenna is noted for its innovative approaches in immunotherapy, particularly its lead IL4 Empowered Superkine, MDNA55.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced the presentation of an abstract during the AACR Annual Meeting 2021 on April 10-15, highlighting early preclinical studies of a novel bispecific Superkine. The abstract, titled Modulation of Immune Responses to Cancer by Bi-specific IL-2/IL-13 Superkines, focuses on an innovative approach combining IL-2 super-agonist with IL-4/IL-13 super-antagonist. The full abstract is available on AACR's website and will be accessible on Medicenna's site post-conference.
Medicenna Therapeutics announced that its CEO, Dr. Fahar Merchant, will present at three major investor conferences in March 2021. These include the H.C. Wainwright Global Life Sciences Conference on March 9, the Oppenheimer 31st Annual Healthcare Conference on March 17, and the Maxim 2021 Emerging Growth Virtual Conference also on March 17. The company's lead product, MDNA55, has shown promise in clinical trials for treating rGBM and has received FDA Fast-Track and Orphan Drug designations.
Medicenna Therapeutics Corp. (NASDAQ: MDNA TSX: MDNA) announced that Dr. Fahar Merchant, CEO, will present at multiple investor conferences in March 2021. These include the H.C. Wainwright Global Life Sciences Conference, with a pre-recorded presentation available on-demand from March 9, and the Oppenheimer 31st Annual Healthcare Conference, featuring a live presentation on March 17. Additionally, Dr. Merchant will participate in a live panel discussion at the Maxim 2021 Emerging Growth Virtual Conference on the same day. Details for accessing the webcasts are available on Medicenna's Investor Relations website.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) will showcase a corporate overview at the 41st Annual Cowen Healthcare Conference on March 2, 2021, at 2:10 PM ET. Dr. Fahar Merchant, President and CEO, will present the company's innovative immunotherapy pipeline, including MDNA11, a next-gen IL-2 Superkine, and MDNA55, an IL4 Empowered Superkine that has completed a Phase 2b trial for rGBM. The presentation can be accessed via a live webcast, with a replay available on Medicenna's Investor Relations website.
Medicenna Therapeutics Corp. (NASDAQ: MDNA; TSX: MDNA) announced that CEO Dr. Fahar Merchant will present a corporate overview at the 41st Annual Cowen Healthcare Conference on March 2, 2021, at 2:10 PM ET. Interested parties can access a live webcast here. The presentation replay will be available on Medicenna's Investor Relations page. The company focuses on immunotherapy with assets like MDNA11 and MDNA55, targeting various cancers and has obtained Fast-Track designation from the FDA.
Medicenna Therapeutics Corp. (NASDAQ: MDNA), a clinical-stage immuno-oncology firm, announced that Dr. Fahar Merchant will present at the 10th Annual Leerink Global Healthcare Conference on February 26, 2021, at 3:00 PM ET. Interested parties can access the live webcast on Medicenna's Investor Relations website.
Medicenna focuses on developing innovative cancer treatments, including MDNA11, a long-acting IL2 Superkine, and MDNA55, an IL4 Empowered Superkine that has completed Phase 2b trials for recurrent glioblastoma (rGBM).
FAQ
What does Medicenna Therapeutics specialize in?
What are superkines?
How does Medicenna's T-MASK platform work?
What are empowered cytokines (ECs)?
What recent achievements has Medicenna made?
What is the company's mission?
How does Medicenna ensure the safety of its treatments?
What are immunocytokines?
How does Medicenna collaborate with other researchers?
What is the financial outlook for Medicenna?
